Hepamerz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Hepamerz (l-ornithine l-aspartate) ## Overview Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. It is thought to reduce ammonia levels by enhancing its detoxification in the liver and kidneys. ## Primary Indications * Treatment of latent and overt hepatic encephalopathy (HE) in patients with cirrhosis. ## Adult Dosing * **Oral:** Typically 3 sachets (18 g total) per day, divided into 3 doses. Some sources suggest up to 6 sachets (36 g total) per day in severe cases, particularly for overt HE. * **Intravenous:** Typically 10 g to 30 g per day, administered as an infusion. The exact dose and duration depend on the severity of HE and local protocol. Often given as 5g or 10g per infusion. ## Pediatric Dosing * Limited data available. Use in pediatric patients is generally not recommended due to lack of established safety and efficacy. ## Dose Adjustments * No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is intended for patients with liver disease. However, caution is advised in severe renal impairment. ## Contraindications * Severe renal insufficiency. * Hypersensitivity to l-ornithine or l-aspartate. ## Adverse Effects * Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain) are the most common. * Rarely, rash or itching. ## Key Drug Interactions * No significant drug interactions have been clearly established. ## Monitoring * Monitor for improvement in neurological symptoms of hepatic encephalopathy. * Monitor electrolytes and renal function, especially in patients with underlying renal issues. ## Clinical Pearls * For oral administration, the contents of the sachets should be dissolved in a sufficient amount of liquid (e.g., water, juice). * The intravenous formulation should be administered slowly to avoid discomfort. * While it aims to reduce ammonia, it does not treat the underlying cause of liver disease. *** *Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete and up-to-date details before making clinical decisions.*